Female Sexual Dysfunction (FSD) Clinical Landscape Report 2024: Only 3 Out of 24 Drugs in the Pipeline are in the Phase III Stage of Development
April 05, 2024 04:34 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Female Sexual Dysfunction (FSD) - Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This report offers a...
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
December 19, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...